KD050 / Sanofi - LARVOL DELTA

MOA study of KD050, an anti-PD-1/IL-15 bi-functional antibody selectively targeted PD-1 positive tumor-infiltrating lymphocytes resulted in robust anti-tumor activity and low systemic toxicity (AACR 2022) - "In conclusion, we demonstrated that KD050 treatment activated different gene pathways which were unique from PD-1 monospecific antibody 38B2, ntKD050 alone or combined with 38B2. These findings indicated that KD050 may have potential to benefit patients that were not responsive to the PD-1/PD-L1 treatment or cytokine treatment."

IO biomarker • Oncology • CD4 • CD8 • GZMB • IL15 • IL2

A novel bi-functional IL15 cytokine fusion antibody selected to kill B7-H4 positive tumor cells (ESMO-IO 2021) - "Kadmon has established a bi-functional cytokine fusion antibody platform, including KD033 (anti-PD-L1/IL15) and KD050 (anti-PD-1/IL15) fusion antibody, to extend the IL15 serum half-life and direct its action to tumors and/or T cells in the tumor microenvironment (TME). Legal entity responsible for the study Kadmon Corporation LLC. Funding Kadmon Corporation LLC."

IO biomarker • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • CD8 • IL15 • IL2 • STAT5 • VTCN1

A novel anti-PD-1/IL15 bi-functional antibody with robust anti-tumor activity in multiple solid tumors (SITC 2021) - "Conclusions We demonstrated that KD050 surrogate had very robust anti-tumor activity and low systemic toxicity in mice bearing multiple solid tumors. These findings suggest that the bi-functional antibody KD050 has encouraging therapeutic potential."

IO biomarker • Colon Cancer • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • CD8 • IL15 • IL2